Kura Oncology (KURA) Stock Price, Quote & News

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 500 8800

Website: kuraoncology.com

Address:

12730 High Bluff Drive, Suite 400, San Diego, United States

American12345 Oct. 4 at 11:12 PM

$KURA what’s your guys target price to sell?

0 · Reply

ibaian Oct. 4 at 4:00 PM

$KURA between. $ 20 and $ 30 by mid of November, majority hold by Institutions,

0 · Reply

Spd2base Oct. 3 at 9:54 PM

$KURA why is RH not showing the current price? It’s showing 9.18?

0 · Reply

Olena Oct. 3 at 9:42 PM

$KURA https://finance.yahoo.com/news/kura-oncology-reports-inducement-grants-113000171.html

0 · Reply

CharlieeMungerTWITS Oct. 3 at 7:50 PM

$KURA $ALDX $CORT $AGIO all bio with catalysts impending winners

0 · Reply

RonIsWrong Oct. 3 at 4:06 PM

$KURA

1 · Reply

darshie Oct. 3 at 2:34 PM

$KURA

0 · Reply

Smellmahass Oct. 3 at 2:25 PM

$KURA Bought as cash per share is 7 plus and chart suggests there will be a run up into pdufa date.

0 · Reply

CharlieeMungerTWITS Oct. 3 at 2:20 PM

$KURA LETS GO 3% a day please

0 · Reply

FITTEST_RETAIL_TRADER Oct. 3 at 2:06 PM

$KURA LFG

0 · Reply

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2025, 5:02 PM EDT - 3 days ago

Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 7:01 AM EDT - 3 days ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 5 days ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

$Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology$

Sep 25, 2025, 5:18 PM EDT - 9 days ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Sep 24, 2025, 7:30 AM EDT - 10 days ago

Kura Oncology to Participate in Upcoming Investor Conference

Sep 19, 2025, 11:03 AM EDT - 15 days ago

Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy

Sep 16, 2025, 10:53 PM EDT - 17 days ago

Kura Oncology, Inc. - Special Call

Sep 16, 2025, 4:01 PM EDT - 18 days ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Sep 10, 2025, 4:44 PM EDT - 24 days ago

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 8:02 AM EDT - 4 weeks ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Aug 28, 2025, 7:30 AM EDT - 5 weeks ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Aug 9, 2025, 10:46 PM EDT - 7 weeks ago

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 2 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 2, 2025, 12:09 AM EDT - 3 months ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jun 12, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 2, 2025, 6:00 PM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$

Jun 1, 2025, 7:00 PM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 22, 2025, 5:30 PM EDT - 4 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 14, 2025, 10:00 AM EDT - 5 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 6, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 1, 2025, 8:48 PM EDT - 5 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 5 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Apr 28, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 24, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 1, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Mar 26, 2025, 7:30 AM EDT - 6 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 4, 2025, 10:12 AM EST - 7 months ago

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Feb 27, 2025, 4:46 AM EST - 7 months ago

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:03 PM EST - 7 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 7:30 AM EST - 8 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 6, 2025, 12:05 PM EST - 8 months ago

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Feb 5, 2025, 4:01 PM EST - 8 months ago

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Jan 6, 2025, 4:30 PM EST - 9 months ago

Kura Oncology Announces Senior Executive Promotions

Dec 18, 2024, 1:46 PM EST - 10 months ago

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Dec 9, 2024, 7:00 AM EST - 10 months ago

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Dec 2, 2024, 7:30 AM EST - 10 months ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Nov 25, 2024, 7:30 AM EST - 11 months ago

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Nov 20, 2024, 5:52 PM EST - 11 months ago

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Nov 20, 2024, 5:00 PM EST - 11 months ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Nov 9, 2024, 5:54 AM EST - 11 months ago

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:09 AM EST - 11 months ago

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report Third Quarter 2024 Financial Results

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Sep 30, 2024, 6:30 PM EDT - 1 year ago

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Sep 17, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

American12345 Oct. 4 at 11:12 PM

$KURA what’s your guys target price to sell?

0 · Reply

ibaian Oct. 4 at 4:00 PM

$KURA between. $ 20 and $ 30 by mid of November, majority hold by Institutions,

0 · Reply

Spd2base Oct. 3 at 9:54 PM

$KURA why is RH not showing the current price? It’s showing 9.18?

0 · Reply

Olena Oct. 3 at 9:42 PM

$KURA https://finance.yahoo.com/news/kura-oncology-reports-inducement-grants-113000171.html

0 · Reply

CharlieeMungerTWITS Oct. 3 at 7:50 PM

$KURA $ALDX $CORT $AGIO all bio with catalysts impending winners

0 · Reply

RonIsWrong Oct. 3 at 4:06 PM

$KURA

1 · Reply

darshie Oct. 3 at 2:34 PM

$KURA

0 · Reply

Smellmahass Oct. 3 at 2:25 PM

$KURA Bought as cash per share is 7 plus and chart suggests there will be a run up into pdufa date.

0 · Reply

CharlieeMungerTWITS Oct. 3 at 2:20 PM

$KURA LETS GO 3% a day please

0 · Reply

FITTEST_RETAIL_TRADER Oct. 3 at 2:06 PM

$KURA LFG

0 · Reply

blueb22 Oct. 3 at 12:32 PM

$KURA - countdown to ESMO started... 11 trading days until 18th Oct ESMO presentation and analysts Conference call (including today) Nice Price uptrend should start now. Also, ER will be in early Nov, and I guess we will hear about what milestone payments they received for Komet-017 studies. I think it will be around $75-100m (as Troy keeps saying significant amount for this and 1st commercial sale which will occur in Dec or Jan after Nov30 approval) and they announced it on 29th Sep, so part of this Q3 balancesheet) AND possibility of 1 month early approval on 25th October along with Sandex's PDUFA date. Good Luck Longs 👍

1 · Reply

SweepCastApp Oct. 3 at 2:59 AM

$KURA: Unusual Options Activity Alerted CALL flow observed 331x contracts at Strike price of $10 Exp on 10/17/2025 with Premium of $31K and showing BULLISH Sentiment

0 · Reply

CharlieeMungerTWITS Oct. 2 at 11:48 PM

$KURA catalyst coming !

0 · Reply

SweepCastApp Oct. 2 at 10:14 PM

$KURA: Unusual Options Activity Alerted CALL flow observed 331x contracts at Strike price of $10 Exp on 10/17/2025 with Premium of $31K and showing BULLISH Sentiment

0 · Reply

FITTEST_RETAIL_TRADER Oct. 2 at 6:30 PM

$KURA

1 · Reply

FITTEST_RETAIL_TRADER Oct. 2 at 5:38 PM

$KURA

0 · Reply

FITTEST_RETAIL_TRADER Oct. 2 at 4:43 PM

$KURA SUPER BULLISH

0 · Reply